Welcome to our dedicated page for Nuo Therapeutics SEC filings (Ticker: AURX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nuo Therapeutics, Inc. (OTCQB: AURX) SEC filings page provides direct access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a reporting company, Nuo Therapeutics submits documents such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and proxy statements on Schedule 14A.
For a commercial-stage medical device and biomedical company focused on chronic wound care, Annual Reports (Form 10-K) and Quarterly Reports (Form 10-Q) are central sources of information. These filings typically describe the Aurix System, summarize the company’s business and risk factors, and discuss reimbursement dynamics for autologous platelet-rich plasma (PRP) therapies used in chronic wound management. They also provide audited or reviewed financial statements and details on capital structure and liquidity.
Current Reports on Form 8-K capture significant events between periodic reports. For Nuo Therapeutics, 8-K filings have included information on recapitalization and exchange agreements that simplified the capital structure, responses to mini-tender offers, and corporate governance matters such as annual meeting results and executive compensation decisions. These filings help investors track material developments affecting the company’s operations and securities.
The company’s Definitive Proxy Statements (DEF 14A) offer insight into board composition, executive compensation programs, and matters submitted to stockholders at annual meetings, including the election of directors and ratification of the independent registered public accounting firm. They also describe how stockholders can participate in corporate governance, for example by submitting proposals or director nominations.
On this page, Stock Titan pairs real-time updates from EDGAR with AI-powered summaries that highlight the key points of lengthy documents, such as complex 10-K risk factor sections or multi-item 8-Ks. Users can quickly see what each filing covers, then review the full text when deeper analysis is needed. Filings related to insider or executive matters, such as compensation decisions disclosed in 8-Ks or proxy statements, can be examined to understand how Nuo Therapeutics aligns management incentives with its chronic wound care business.
Nuo Therapeutics, Inc. files its annual report describing a small but fast-growing chronic wound-care business built around its Aurix autologous platelet-rich plasma system. Product revenue rose from approximately $1.4 million in 2024 to $3.1 million in 2025, with total 2025 revenue of about $3.3 million including distribution fees.
The company remains unprofitable, recording a net loss of roughly $2.5 million in 2025 and warning of substantial doubt about its ability to continue as a going concern without additional capital. As of June 30, 2025, non-affiliate market value was about $41.1 million, and 48,289,296 shares of common stock were outstanding as of March 26, 2026.
Nuo highlights expanding Medicare reimbursement for Aurix, including 2026 national average rates of $2,108 per treatment in hospital outpatient settings and $1,064 in physician offices. A new U.S. distribution agreement with Smith+Nephew adds a private-label channel with minimum annual purchase commitments and up to $2.25 million in fees, but the company still faces single-supplier risks, intense competition, heavy regulatory oversight and the ongoing need for financing.
Nuo Therapeutics, Inc. disclosed that investor Paul Anthony Jacobs has a significant passive stake in its common stock. As of 01/23/2026, he beneficially owned 3,183,500 shares of common stock, including 43,500 shares issuable upon exercise of immediately exercisable warrants, representing 6.6% of the outstanding class.
Jacobs reports sole voting and dispositive power over all of these shares and states they are not held for the purpose of changing or influencing control of the company.
Nuo Therapeutics director and 10% owner Scott M. Pittman reported receiving several derivative awards in the form of warrants linked to common stock at an exercise price of $1.5 per share on January 23, 2026. The grants include Commitment Warrants, Origination Initial Warrants, Capital Initial Warrants, Origination Second Warrants, Capital Second Warrants, and Prepayment Warrants, each giving the right to buy Nuo Therapeutics common stock and expiring on January 23, 2031.
Certain Second Warrants will vest, if at all, on September 30, 2026 only if a Second Funding occurs under a Loan and Security Agreement dated January 21, 2026. The Prepayment Warrants will vest, if at all, upon a Prepayment event, but no later than December 31, 2028, and the disclosed amount reflects the maximum number of shares issuable upon such a Prepayment. The company’s Board and non-employee directors approved the loan arrangement and the related warrant and share issuances.
Nuo Therapeutics investor Scott M. Pittman reports beneficial ownership of 5,610,050 shares of common stock, or 11.6% of the company, based on 48,281,625 shares outstanding as of January 21, 2026. His holdings include 5,400,000 shares held directly, 30,050 shares issuable upon exercise of newly received warrants, and 180,000 shares underlying options.
The amendment also describes a secured loan arrangement where Pittman has loaned $200,000 to Nuo Therapeutics and committed to an additional $210,000 if requested. The notes bear interest at 10%, rising to 12% if a second closing occurs, and mature on December 31, 2028. Interest and certain prepayment fees are payable in stock warrants rather than cash, with multiple warrant series exercisable at $1.50 per share and expiring January 23, 2030, giving Pittman additional potential equity exposure through commitment, origination, capital coverage, prepayment, second-closing, and interest warrants.
Nuo Therapeutics, Inc. entered into a Loan and Security Agreement providing up to $1.6 million in secured term loans, with $1.0 million funded on January 23, 2026 and an additional $600 thousand available on September 30, 2026 if drawn. The loans bear interest at an annual rate of 10%, rising to 12% if the second tranche is funded, and mature on December 31, 2028, with principal repaid quarterly from March 31, 2027. The debt is secured by a lien on all company assets and includes mandatory prepayment upon certain equity financings, change in control events, or default, with prepayment fees paid in warrants instead of cash.
As part of this financing, Nuo issued multiple series of common stock warrants at a $1.50 exercise price, including fees, capital coverage, prepayment, and interest payment warrants, some of which vest only if the second tranche funds or if prepayment events occur. At closing the company issued warrants immediately exercisable for an aggregate of 148,000 shares and conditionally or potentially exercisable warrants for additional shares, including up to 226,000 shares in Interest Warrants tied to the full $1.6 million funding. Two significant shareholders, including director Scott M. Pittman, participated as lenders and received a portion of these warrants.
Nuo Therapeutics CEO/CFO and director David Jorden reported an insider stock option exercise. On 01/01/2026, he exercised an option to purchase 125,000 shares of Nuo Therapeutics, Inc. common stock at an exercise price of $0.40 per share using a net exercise method.
The company withheld 25,381 shares, valued at the closing price of $1.97 per share, to cover the exercise cost, and Jorden received 99,619 shares of common stock. Following these transactions, he directly beneficially owned 2,046,374 shares of Nuo Therapeutics common stock, and the reported option position was reduced to zero.
Nuo Therapeutics director reports option exercise and share withholding
A director of Nuo Therapeutics, Inc. reported transactions in the company’s common stock dated 12/17/2025. The director exercised an option to purchase 68,750 shares of common stock at an exercise price of $0.4 per share, receiving 55,000 shares on a net basis. The issuer withheld 13,750 shares of common stock underlying the option to cover the exercise price, using the closing price of $2.00 per share. Following these transactions, the director directly beneficially owned 172,654 shares of Nuo Therapeutics common stock.
Nuo Therapeutics, Inc. reported the results of its 2025 Annual Meeting of Stockholders held on December 16, 2025. Stockholders elected four directors to the board, ratified the company’s independent auditor, and approved executive compensation on an advisory basis.
Director nominees David E. Jorden, Paul D. Mintz, Scott M. Pittman, and C. Eric Winzer each received about 33.7 million votes in favor, with only a few thousand votes withheld and 2,237,142 broker non-votes. Stockholders ratified MaloneBailey LLP as independent registered public accounting firm with 35,917,807 votes for and 12,899 against, and approved the say-on-pay proposal with 33,653,458 votes for and 40,106 against, plus 2,237,142 broker non-votes.
Nuo Therapeutics, Inc. director reports stock option exercise. A director of Nuo Therapeutics exercised an option to purchase 50,000 shares of common stock at an exercise price of $0.40 per share through a net exercise on December 9, 2025. The transaction resulted in the director receiving 40,909 shares of common stock, while 9,091 shares underlying the option were withheld to cover the exercise price using a closing market price of $2.20 per share. Following these transactions, the director beneficially owns 108,294 shares of Nuo Therapeutics common stock in direct ownership.
Nuo Therapeutics, Inc. director filed a Form 4 reporting an option exercise and related share withholding. On 12/09/2025, the insider exercised an option to purchase 50,000 shares of common stock at an exercise price of $0.40 per share. As part of a net exercise, the issuer withheld 9,091 shares of common stock at a closing price of $2.20 to cover the exercise cost, and the reporting person received 40,909 shares of common stock. Following these transactions, the insider directly beneficially owned 108,294 shares of Nuo Therapeutics common stock.